Search Results

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.

• Authors : Herold, Kevan C.¹; Gitelman, Stephen E.²; Gottlieb, Peter A.³

Subjects: *TYPE 1 diabetes; *DIABETES in children; *TYPE 2 diabetes

• Source: Diabetes Care. Oct2023, Vol. 46 Issue 10, p1848-1856. 9p.

Record details

Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.

• Authors : Herold, Kevan C.^1,2 ; Reynolds, Jesse³; Dziura, James^2,4

Subjects: *TYPE 1 diabetes; *EXENATIDE; *GLUCAGON-like peptide-1 receptor

• Source: Diabetes, Obesity & Metabolism. Nov2020, Vol. 22 Issue 11, p2045-2054. 10p.

Record details

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

• Authors : Herold, Kevan C.¹ ; Bundy, Brian N.²; Long, S. Alice³

• Source: New England Journal of Medicine. 8/15/2019, Vol. 381 Issue 7, p603-613. 11p.

Record details

Why is COVID-19 generally milder in children?

• Authors : Pierce, Carl A.¹; Herold, Kevan C.^2,3 ; Herold, Betsy C.^1,4

Subjects: *COVID-19; *CORONAVIRUS diseases; *COVID-19 pandemic

• Source: Science. 9/9/2022, Vol. 377 Issue 6611, p1145-1145. 2/3p.

Record details

Endocrinology research-reflecting on the past decade and looking to the next.

• Authors : Herold, Kevan C.¹ ; Majzoub, Joseph A.² ; Melmed, Shlomo³

Subjects: *PITUITARY gland physiology; *ENDOCRINOLOGY; *TYPE 1 diabetes

• Source: Nature Reviews Endocrinology. Nov2015, Vol. 11 Issue 11, p672-680. 9p.

Record details

Thinking bedside at the bench: the NOD mouse model of T1DM.

• Authors : Reed, James C.¹; Herold, Kevan C.^1,2

Subjects: *PEOPLE with diabetes; *CHRONICALLY ill; *DIABETES

• Source: Nature Reviews Endocrinology. May2015, Vol. 11 Issue 5, p308-314. 7p.

Record details

βCell death and dysfunction during type 1 diabetes development in at-risk individuals.

• Authors : Herold, Kevan C.¹ ; Usmani-Brown, Sahar²; Ghazi, Tara¹

Subjects: *CELL death; *CELLS; *TYPE 1 diabetes

• Source: Journal of Clinical Investigation. Mar2015, Vol. 125 Issue 3, p1163-1173. 11p. 1 Color Photograph, 1 Diagram, 2 Charts, 4 Graphs.

Record details

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005–1013.

• Authors : Russell, William E.¹ ; Moore, Daniel J.²; Herold, Kevan C.³

• Source: Diabetes Care. Nov2023, Vol. 46 Issue 11, pe210-e211. 2p.

Record details

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.

• Authors : Herold, Kevan C (AUTHOR); Gitelman, Stephen E (AUTHOR); Ehlers, Mario R (AUTHOR)

• Source: Diabetes. Nov2013, Vol. 62 Issue 11, p3766-3774. 9p.

Record details

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial.

• Authors : Herold, Kevan C.¹ ; Gitelman, Stephen E.²; Ehlers, Mario R.³

Subjects: *TYPE 1 diabetes; *THERAPEUTIC use of monoclonal antibodies; *TREATMENT of diabetes

• Source: Diabetes. Nov2013, Vol. 62 Issue 11, p3766-3774. 9p. 1 Diagram, 3 Charts, 4 Graphs.

Record details